Free Trial
NASDAQ:OTLK

Oncobiologics (OTLK) Stock Price, News & Analysis

Oncobiologics logo
$2.68 +0.28 (+11.41%)
As of 03:29 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Oncobiologics Stock (NASDAQ:OTLK)

Key Stats

Today's Range
$2.38
$2.69
50-Day Range
$1.58
$2.77
52-Week Range
$0.87
$8.32
Volume
3.13 million shs
Average Volume
820,678 shs
Market Capitalization
$90.14 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.60
Consensus Rating
Moderate Buy

Company Overview

Oncobiologics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
43rd Percentile Overall Score

OTLK MarketRank™: 

Oncobiologics scored higher than 43% of companies evaluated by MarketBeat, and ranked 667th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Oncobiologics has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Oncobiologics has only been the subject of 2 research reports in the past 90 days.

  • Read more about Oncobiologics' stock forecast and price target.
  • Earnings Growth

    Earnings for Oncobiologics are expected to grow in the coming year, from ($2.27) to ($0.20) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Oncobiologics is -4.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Oncobiologics is -4.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Percentage of Shares Shorted

    8.89% of the float of Oncobiologics has been sold short.
  • Short Interest Ratio / Days to Cover

    Oncobiologics has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Oncobiologics has recently increased by 16.34%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Oncobiologics does not currently pay a dividend.

  • Dividend Growth

    Oncobiologics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    8.89% of the float of Oncobiologics has been sold short.
  • Short Interest Ratio / Days to Cover

    Oncobiologics has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Oncobiologics has recently increased by 16.34%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Oncobiologics has a news sentiment score of 0.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 15 news articles for Oncobiologics this week, compared to 3 articles on an average week.
  • Search Interest

    17 people have searched for OTLK on MarketBeat in the last 30 days. This is an increase of 13% compared to the previous 30 days.
  • MarketBeat Follows

    4 people have added Oncobiologics to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Oncobiologics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 4.80% of the stock of Oncobiologics is held by insiders.

  • Percentage Held by Institutions

    Only 11.20% of the stock of Oncobiologics is held by institutions.

  • Read more about Oncobiologics' insider trading history.
Receive OTLK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oncobiologics and its competitors with MarketBeat's FREE daily newsletter.

OTLK Stock News Headlines

Oncobiologics FY2025 EPS Estimate Increased by HC Wainwright
The Trump Dump is starting; Get out of stocks now?
The first 365 days of the Trump presidency… Will be the best time to get rich in American history.tc pixel
Oncobiologics (OTLK) to Release Quarterly Earnings on Wednesday
OTLK Outlook Therapeutics, Inc. - Seeking Alpha
See More Headlines

OTLK Stock Analysis - Frequently Asked Questions

Oncobiologics' stock was trading at $1.89 at the beginning of 2025. Since then, OTLK shares have increased by 38.9% and is now trading at $2.6250.

Oncobiologics, Inc. (NASDAQ:OTLK) released its earnings results on Thursday, August, 14th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.42) by $0.02. The firm had revenue of $1.51 million for the quarter, compared to the consensus estimate of $1.66 million.

Shares of Oncobiologics reverse split on the morning of Thursday, March 14th 2024.The 1-20 reverse split was announced on Thursday, March 14th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, March 14th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Top institutional investors of Oncobiologics include Russell Investments Group Ltd. (0.07%) and Group One Trading LLC. Insiders that own company stock include Jeff Evanson, Terry Dagnon, Kurt J Hilzinger, Lawrence A Kenyon and Yezan Munther Haddadin.
View institutional ownership trends
.

Shares of OTLK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Oncobiologics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Moderna (MRNA), Intel (INTC) and Sorrento Therapeutics (SRNE).

Company Calendar

Last Earnings
8/14/2025
Today
8/22/2025
Fiscal Year End
9/30/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:OTLK
CIK
1649989
Fax
N/A
Employees
20
Year Founded
N/A

Price Target and Rating

High Price Target
$21.00
Low Price Target
$3.00
Potential Upside/Downside
+298.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.57)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$75.37 million
Net Margins
N/A
Pretax Margin
-2,886.25%
Return on Equity
N/A
Return on Assets
-332.30%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.67
Quick Ratio
0.57

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($1.11) per share
Price / Book
-2.17

Miscellaneous

Outstanding Shares
33,570,000
Free Float
31,957,000
Market Cap
$80.90 million
Optionable
Optionable
Beta
0.26

Social Links

The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NASDAQ:OTLK) was last updated on 8/22/2025 by MarketBeat.com Staff
From Our Partners